Destiny Pharma Plc, the UK antibiotic developer, has appointed Shaun Claydon as chief financial officer, succeeding Simon Sacerdoti who is stepping down having led the company’s initial public offering on AIM in 2017. Mr Claydon was previously CFO of Creabilis, a specialty pharma company acquired by Sienna Biopharmaceuticals in 2016. Prior to this, he was CFO and chief operating officer of Orteq Sports Medicine, a medical device company. Mr Claydon holds a BA in economics from the University of Leeds, UK.
Destiny Pharma announced the appointment on 25 October 2018.
Copyright 2018 Evernow Publishing Ltd